The Essays
- Nº 09Essay
Two Ledgers, One Laboratory
The private laboratory is a business and a clinical service. The two are not in conflict — they never were.
- Nº 08Essay
The Antibody That Half the Market Rents
Five diagnostics platforms are racing toward Alzheimer's blood testing. Two licensed the same antibody from the same small biotech. A third group hasn't entered the avenue at all.
- Nº 07Essay
The Test That Wasn't Done
Market sizing reports count what gets billed. The number that matters more is what should have been ordered and wasn't — and the gap is structural, not geographic.
- Nº 06Essay
The Race Nobody Can Win
Routine clinical chemistry has converged into an engineering commodity. The differentiation that actually matters has moved one floor up, into the specialised immunoassay niches where a wrong number hurts a patient.
- Nº 05Commercial Design
The Referring Physician Is Not a Contact
Most IVD organisations manage their referring-physician relationships as a sales pipeline. That is the wrong frame. The physician who sends samples is choosing a diagnostic partner — and the criteria have nothing to do with price.
- Nº 04Framework
How to Actually Read a Vendor
A working method for evaluating a diagnostics platform without letting the flag on the box decide for you. Seven questions, weighted to your own laboratory.
- Nº 03Field Notes
Mexico, Where the Philosophies Collide
Price-sensitive, clinically serious, and built on the comodato, the Mexican market turns every analyzer purchase into a multi-year stress test. Here is what it reveals.
- Nº 02Essay
Two Philosophies of the Analyzer
Asian and Western diagnostics are not separated by quality anymore. They are separated by what they choose to optimise — and that distinction is far more useful to a buyer.
- Nº 01Manifesto
Reading the Standard Curve
After sixteen years between Asian and Western diagnostics, I am done pretending the old map still works. Here is the question this notebook exists to answer.